The revenue for EDP-938 is expected to reach an annual total of $14 mn by 2034 in the US based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.

EDP-938 Overview

EP-938 is under development for the treatment of respiratory syncytial virus (RSV-A and RSV-B) infections. The drug candidate is administered through oral route and it is a new chemical entity, a non-fusion inhibitor that targets Nucleocapsid protein (N protein).

Enanta Pharmaceuticals Overview

Enanta Pharmaceuticals (Enanta) is a clinical-stage biotechnology company that develops small molecule drugs for viral infections. The company’s pipeline includes glecaprevir, EDP-514, EDP-938, EDP-323, EDP-235, EDP-305, EDP – 297.h Its pipeline candidates treat hepatitis C virus (HCV), Hepatitis B virus (HBV), respiratory syncytial virus (RSV), COVID-19 and non-alcoholic steatohepatitis (NASH). Its brands include Mavyret and Vieira pak. The company works in partnership with the National Institute of Allergy and Infectious Diseases, AbbVie Inc, Novartis, Shionogi Inc to discover two protease inhibitor compounds. Enanta is headquartered in Watertown, Massachusetts, the US.

The company reported revenues of (US Dollars) US$86.2 million for the fiscal year ended September 2022 (FY2022), a decrease of 11.2% over FY2021. The operating loss of the company was US$123.8 million in FY2022, compared to an operating loss of US$109.6 million in FY2021. The net loss of the company was US$121.8 million in FY2022, compared to a net loss of US$79 million in FY2021. The company reported revenues of US$17.8 million for the second quarter ended March 2023, a decrease of 24.5% over the previous quarter.

For a complete picture of EDP-938’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.

This content was updated on 2 September 2023

Premium Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, drug margins and company expenses. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate valuation, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA) and phase transition success rate (PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.